Managed Care Stocks: Medicare Advantage Growth and the MCO Compounding Machine

A $1 Trillion Industry Hiding in Plain Sight

Managed care is boring. That's the point.

While investors chase the next AI darling or debate whether crypto has bottomed, the five largest U.S. managed care organizations — UnitedHealth Group, Elevance Health, Cigna Group, Centene, and Humana — collectively process over $1 trillion in annual premium revenue and cover more than 150 million Americans. They sit between employers, government programs, hospitals, doctors, and pharmacies, taking a thin margin on an enormous volume of healthcare transactions. That thin margin, applied to a market growing at 7–9% annually with demographic tailwinds that are mathematically impossible to reverse, has produced some of the most consistent compounding in American public markets.

UnitedHealth has returned roughly 3,200% over the past 20 years. Elevance (formerly Anthem) has returned approximately 1,800%. These aren't tech multiples driven by narrative; they're earnings growth driven by volume, pricing, and vertical integration. Our analysis suggests the next decade looks similar — and the current regulatory noise is creating entry points for patient capital.

Medicare Advantage: The Growth Engine Wall Street Still Underestimates

Medicare Advantage (MA) is the privatized alternative to traditional fee-for-service Medicare. Beneficiaries choose an MA plan from a private insurer (UnitedHealth, Humana, etc.), and CMS pays that insurer a per-member-per-month capitated rate based on county benchmarks and risk-adjusted patient acuity. The insurer then manages the beneficiary's total cost of care, profiting if actual medical costs come in below the capitated payment.

Here's what matters: MA penetration crossed 50% of all Medicare-eligible beneficiaries in 2023, reaching approximately 33.8 million enrollees as of January 2025, per KFF data. A decade ago, it was 30%. Two decades ago, 13%. The growth has been relentless because MA plans typically offer richer benefits than traditional Medicare — dental, vision, hearing, gym memberships, over-the-counter drug allowances — funded by the quality bonus payments that CMS awards to 4+ star plans. Seniors are rationally choosing more benefits at similar or lower cost.

We think MA penetration reaches 60% by 2030 and possibly 70% by 2035. The Congressional Budget Office projects MA enrollment will grow to 47 million by 2033. That's 13 million incremental lives, each carrying $12,000–$18,000 in annual per-member premium value. Simple multiplication: 13 million members at $15,000 average premium equals $195 billion in incremental annual revenue for the MA industry. UnitedHealth and Humana, which together control roughly 45% of the MA market, capture the largest share.

Medical Loss Ratios: The Only Number That Actually Matters

If you invest in MCOs and you don't track medical loss ratios obsessively, you're flying blind. The MLR is the percentage of premium revenue spent on medical claims. Everything else in the P&L — admin costs, SG&A, investment income — is secondary noise. A 100-basis-point MLR swing on UnitedHealth's $280 billion premium base moves pre-tax earnings by $2.8 billion. That's roughly $3 per share.

Target MLRs vary by business mix. UNH runs consolidated at 82–84%. Elevance, with its heavier Medicaid population, operates at 86–88%. Humana's Medicare-concentrated book typically lands at 86–87% but spiked above 89% in late 2024 on elevated utilization (more on that shortly). Centene, the Medicaid specialist, runs high 87–89% MLRs reflecting the lower-margin, higher-volume nature of Medicaid.

The ACA mandates minimum MLRs — 85% for large group, 80% for individual and small group — which effectively caps insurer margins on the downside (rebates are owed if MLRs run too low). But this floor also creates a predictable margin framework: MCOs don't try to minimize medical costs to zero. They manage to a target band that balances profitability with regulatory compliance and member satisfaction. It's a regulated utility-like dynamic, and that predictability is precisely why these stocks compound.

Stock-by-Stock Breakdown: The Big Five MCOs

UnitedHealth Group (UNH): The Compounding Machine

We've written about UNH in our healthcare demographics analysis, but it bears repeating here in the MCO context. UnitedHealth isn't just a health insurer. It's a vertically integrated healthcare conglomerate where the insurance arm (UnitedHealthcare) feeds data and patients into the services arm (Optum), which delivers care (OptumHealth, 103M+ consumers), manages pharmacy benefits (OptumRx, ~1.4 billion scripts annually), and sells analytics (OptumInsight). The flywheel is extraordinarily difficult to replicate.

Optum now generates over $230 billion in revenue — larger than all but a handful of U.S. companies — and grows at 15%+ annually. This is not insurance revenue. This is healthcare services revenue with fundamentally different margin and growth characteristics. Optum's operating margin runs 7–8% versus 4–5% for the insurance segment, and its growth rate is roughly double. By 2028, we expect Optum to represent 65%+ of UNH's total operating earnings, effectively transforming the company from “an insurer with a services arm” into “a healthcare platform with an insurance arm.”

At 17–18x forward earnings for a business compounding EPS at 13–15%, generating 25%+ ROE, and raising its dividend 15% per year, we think UNH is the single best risk-adjusted holding in healthcare. Not cheap in absolute terms. But cheap for the quality.

Elevance Health (ELV): The Underappreciated Value Play

Elevance operates the largest collection of Blue Cross Blue Shield licenses in the country, covering 14 states with deep local market share that is nearly impossible to displace. The BCBS brand carries enormous trust with employers and consumers. Elevance's commercial enrollment is sticky because switching health insurers is operationally painful for large employers — provider networks need to be rebuilt, employee communications reissued, and administrative systems reconfigured.

What the market underappreciates is Elevance's Medicaid franchise. ELV is the largest Medicaid managed care company in the U.S., serving approximately 12 million Medicaid members. Medicaid is a lower-margin business (MLRs run 88–90%), but it's enormous — total Medicaid spending exceeds $800 billion annually — and the shift from fee-for-service to managed Medicaid is an ongoing structural trend. States prefer managed care because it transfers actuarial risk to private insurers and imposes cost discipline on a population with high utilization variability.

Elevance's Carelon services arm (formerly Diversified Business Group) is its attempt to build an Optum equivalent — pharmacy services, behavioral health management, and care delivery. Carelon generates roughly $50 billion in revenue and is growing double digits. It's earlier innings than Optum, which means more runway. At approximately 12x forward earnings, ELV trades at a 30%+ discount to UNH. Some of that discount is deserved (less integrated, smaller services arm), but our view is the gap narrows as Carelon scales.

Humana (HUM): The Medicare Bet — Concentrated and Volatile

Humana is the purest play on Medicare Advantage in public markets. Approximately 85% of Humana's insurance premium revenue comes from MA, versus 30–35% for UnitedHealth and under 15% for Elevance. This concentration is both the bull case and the bear case. When MA rates are favorable and utilization is manageable, Humana compounds beautifully. When either variable turns adverse, the stock gets punished — hard.

Late 2024 and early 2025 were a punishing period. Humana reported MLRs spiking above 89% due to elevated utilization in outpatient procedures and supplemental benefits. The stock dropped over 35% from its 2023 highs. Management guided to a “reset year” for 2025, pulling back on benefit richness in certain markets and exiting unprofitable counties. Our take: this is a cyclical trough, not a structural break. Humana has navigated utilization spikes before (2016, 2019) and restored margins within 2–3 quarters by repricing bids and tightening care management.

Humana's CenterWell platform (primary care clinics, home health, pharmacy) serves a similar strategic function to Optum — moving downstream into care delivery to capture margin that otherwise flows to providers. CenterWell operates roughly 300 senior-focused primary care centers and is the third-largest home health provider in the country. It's subscale relative to Optum but growing 20%+ annually. If Humana can stabilize its MLR while scaling CenterWell, the stock at 18–20x forward earnings offers meaningful upside. But position sizing should reflect the concentration risk.

Cigna Group (CI): PBM-Heavy and Under Legislative Scrutiny

Cigna is a tale of two businesses. The health insurance segment (Cigna Healthcare) is a solid commercial employer franchise with 20+ million members. But the company's identity — and its revenue — is dominated by Esprinet, its pharmacy benefit management arm. Esprinet generates approximately $170 billion in annual revenue (yes, that dwarfs the insurance segment) by negotiating drug prices, managing formularies, and processing pharmacy claims for employers and health plans.

PBM revenue is high-volume, low-margin, and increasingly controversial. Bipartisan congressional scrutiny of PBM spread pricing — where PBMs charge health plans more for a drug than they reimburse the pharmacy, pocketing the difference — has intensified through 2025. The FTC's interim report on PBM practices, published in mid-2024, was scathing in its criticism of rebate opacity and vertical integration conflicts. Multiple bills in Congress would require pass-through pricing, ban spread pricing in Medicaid, or mandate PBM fiduciary duties to plan sponsors.

We think PBM reform of some kind is coming. The question is severity. Mild reform (increased transparency, some spread pricing limits) is manageable. Aggressive reform (fiduciary duty, full pass-through pricing) could compress Esprinet's margins by 15–25%. Cigna trades at roughly 11x forward earnings, cheap even by MCO standards, but the discount reflects real legislative risk. We'd rather own UNH (whose OptumRx faces similar PBM scrutiny but represents a smaller share of total earnings) than CI as a standalone PBM bet.

Centene (CNC): The Medicaid Specialist at a Deep Discount

Centene is the largest Medicaid managed care company in the United States, covering approximately 16 million Medicaid and CHIP beneficiaries across 29 states. The company also operates the largest ACA marketplace exchange business, with over 4 million individual exchange members. At 9–10x forward earnings, Centene is the cheapest MCO by a wide margin.

The discount reflects legitimate concerns. Medicaid is a low-margin business where state contracts are rebid every 3–5 years, creating revenue concentration risk. The Medicaid redetermination process (which resumed in 2023 after the COVID-era continuous enrollment provision expired) disenrolled approximately 20 million people, reducing membership at Centene and peers. And Centene's management history has been uneven — a corporate governance overhaul in 2022 followed allegations of undisclosed related-party transactions under previous leadership.

But here's the contrarian case: Medicaid isn't going away. Total Medicaid enrollment has stabilized around 80 million post-redetermination. The managed Medicaid penetration rate is still increasing (currently about 72% of Medicaid beneficiaries are in managed care plans, up from 55% a decade ago). And Centene's exchange business is a genuine growth asset, benefiting from enhanced ACA subsidies that were extended through 2025 and may be made permanent. If Centene can execute operationally under its improved governance structure, the stock at 9x earnings with mid-single-digit EPS growth is a reasonable value bet.

V28 Risk Adjustment Changes: A Technical Headwind, Not a Structural Threat

CMS introduced the V28 risk adjustment model in 2024, phasing in over three years (2024–2026), to recalibrate how patient acuity is measured and how MA plans are reimbursed for sicker patients. The practical impact: V28 removes certain diagnosis codes from the risk adjustment formula, reduces the weight of others, and generally lowers the risk scores that MA plans can claim. Lower risk scores mean lower CMS payments per member.

The industry estimated V28 created a 2–3% headwind to MA revenue per member over the phase-in period. Humana, with its concentrated MA book, was hit hardest — the company attributed a meaningful portion of its 2024–2025 margin compression to V28 coding changes disrupting its risk adjustment revenue. UnitedHealth absorbed the impact more gracefully because its Optum data infrastructure enables faster recoding and documentation improvement.

Our view: V28 is a one-time transition, not a permanent margin reset. MCOs have navigated every prior risk adjustment model change (V12, V21, V22, V24, V25, V28) by improving clinical documentation, investing in coding accuracy, and adjusting benefit designs. By 2027, the V28 phase-in will be complete and fully reflected in bid pricing. Investors selling MCOs on V28 headlines are confusing a transitory headwind with structural impairment — and that confusion creates buying opportunities.

Post-COVID Utilization: The Trend That Caught Humana (and Why It's Normalizing)

The COVID pandemic suppressed healthcare utilization in 2020–2021, creating a brief MLR windfall for MCOs as premiums kept flowing but patients stayed home. The hangover arrived in 2023–2025. Deferred care came flooding back — orthopedic surgeries, cancer screenings, behavioral health visits, elective procedures — pushing utilization above pre-pandemic baselines.

Humana bore the brunt because its elderly MA population had the highest deferred care backlog and the greatest supplemental benefit utilization (dental, vision, and hearing benefits are heavily used by 65+ populations). But the utilization spike wasn't unique to Humana. UNH saw its 2024 MLR creep toward the high end of guidance. Elevance flagged Medicaid utilization above actuarial expectations. The entire sector experienced the same dynamic at different intensities.

We think the catch-up effect is largely exhausted by mid-2026. Utilization data from the major health systems (HCA, Tenet, CommonSpirit) shows procedure volumes stabilizing near long-term trend lines. The key forward variable is whether utilization structurally resets higher due to improved access (telehealth expansion, site-of-care shifts to outpatient) or returns to historical actuarial patterns. Our base case: utilization normalizes 2–3% above pre-COVID levels permanently, which MCOs can accommodate through normal annual premium repricing. The bear case — a structural step-change in utilization growth rates — would require a fundamental rethinking of MCO margin structures. We assign that scenario a 15–20% probability.

Star Ratings and the Quality Flywheel

CMS Star Ratings are the most underappreciated driver of MCO economics. The system rates MA plans on a 1–5 scale across approximately 40 quality measures covering clinical outcomes, member experience, complaints, and administrative performance. Plans scoring 4 stars or above receive a 5% quality bonus on their CMS benchmark payments. That bonus funds richer benefits, which attract more members, which generates more premium revenue, which funds further quality improvements. It's a flywheel, and it overwhelmingly favors scale players.

In 2025, roughly 74% of MA enrollees were in 4+ star plans. UnitedHealth consistently maintains the highest proportion of 4+ star enrollment, and Humana historically ran close behind until the V28 disruption temporarily impacted some of its plan ratings. The financial stakes are enormous: for a plan with 1 million MA members and a $12,000 average benchmark, a 5% quality bonus translates to $600 million in additional annual revenue. Losing star status is a slow-motion catastrophe — it takes 2–3 years to recover, and member losses compound during the recovery period.

PBM Reform and the Inflation Reduction Act: Sizing the Legislative Risk

Two legislative vectors deserve separate attention because they affect different MCOs in different ways.

PBM Reform: Real Risk, Uneven Exposure

The three largest PBMs — CVS Caremark, Cigna's Esprinet, and UnitedHealth's OptumRx — control approximately 80% of the U.S. prescription market. Congressional critics allege PBMs extract value from both sides of the transaction: negotiating rebates from drug manufacturers (some of which are retained rather than passed through to patients) and setting reimbursement rates for pharmacies that sometimes fall below acquisition cost.

The FTC's 2024 interim report accused the three largest PBMs of steering patients toward affiliated pharmacies, inflating drug costs through rebate-driven formulary placement, and profiting from spread pricing in Medicaid. Multiple reform bills are circulating — the most aggressive would impose fiduciary duties on PBMs and mandate 100% rebate pass-through.

The exposure is concentrated. For Cigna, Esprinet represents roughly 75% of consolidated revenue (though a much smaller share of operating profit due to PBM's thin margins). For UNH, OptumRx is one of four Optum segments and represents perhaps 15–20% of consolidated operating profit. Reform that crushes PBM margins hurts Cigna existentially but is manageable for UNH. This asymmetry is why CI trades at 11x and UNH at 17x. The market is already pricing differential risk — the question is whether it's priced correctly.

Inflation Reduction Act Drug Pricing: Pharma's Problem, MCOs' Tailwind

The IRA's Medicare drug price negotiation provisions — which applied to 10 drugs in 2026 and will expand to 20 drugs by 2029 — are primarily a pharma headwind, not an MCO headwind. In fact, lower drug prices under Medicare Part D reduce pharmacy costs for MA plans, which could modestly improve MLRs. The IRA also caps Medicare Part D out-of-pocket costs at $2,000 annually beginning in 2025, which may increase plan attractiveness and drive MA enrollment growth.

The indirect risk to MCOs is that IRA savings reduce the government's urgency to fund generous MA rate increases, since lower drug costs also lower traditional Medicare's per-beneficiary spending (which sets the benchmark for MA rates). But this is a second-order effect, and MA rate growth has averaged 3–5% annually over the past decade regardless of drug pricing dynamics.

Why MCOs Compound Despite Regulatory Noise: The 30-Year Track Record

Here is the fact that should anchor every managed care investment discussion: the S&P Managed Care sub-index has delivered approximately 15–16% annualized total returns over the past 20 years, outperforming the S&P 500, the NASDAQ, and the S&P Healthcare index. This outperformance occurred through the ACA passage (2010), the Medicaid expansion (2014), annual MA rate cut scares, multiple utilization spikes, PBM controversies, and constant political threats to “fix” healthcare.

The pattern repeats with remarkable consistency. A regulatory headline creates a 10–20% selloff. Investors panic. MCOs adjust — repricing, restructuring benefits, optimizing networks, passing through costs. Earnings recover within 12–18 months. The stock not only recovers but reaches new highs because underlying volume growth (aging population, MA penetration, Medicaid managed care expansion) continues uninterrupted.

We are not arguing that regulatory risk is fake. Individual policy changes can permanently impair specific revenue streams (PBM reform could structurally compress spread pricing). But at the sector level, MCOs are intermediaries in a $4.8 trillion market growing at 7–9% annually with an aging population that will require more healthcare regardless of regulatory structure. The form of the intermediary role may evolve. The need for it will not. That's the compounding thesis. It's not exciting. It works.

Portfolio Construction: How to Size MCO Exposure

Our recommended framework: UnitedHealth as the core position (60–70% of MCO allocation), with satellite positions in one or two names that provide specific sub-sector exposure at lower valuations.

Total MCO allocation within a diversified equity portfolio should be 5–10%. These are steady compounders, not high-beta momentum trades. Size accordingly and let time do the work. The demographic math — 10,000 new Medicare-eligible Americans daily, MA penetration climbing toward 60–70%, Medicaid managed care expansion continuing — compounds regardless of quarterly MLR noise or CMS rate notice headlines.

Frequently Asked Questions